Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals Of The Week: Pfizer/Protalix, AstraZeneca/Targacept, Chiesi/Phenomix

Executive Summary

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1

You may also be interested in...

Phenomix And Chiesi Partner For Phase III DPP-4 Drug In Europe

After the deal, Phenomix reports it has an "excellent cash position."

Antibodies Licensed From Trellis Bring MedImmune More Potential RSV Candidates

Using very high throughput screening, Trellis identified antibodies in human blood that had been selected by the immune system to fight the virus.

Pfizer Partners With Protalix On Gaucher Drug Eyeing Lower Cost Plant-Based Production

Pfizer agrees to pay $60 million upfront for rights to taliglucerase, an investigational competitor to Genzyme's Cerezyme.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts